Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2017

Open Access 01-12-2017 | Research article

Evaluation of the impact of disease prevention measures: a methodological note on defining incidence rates

Authors: Yin-Bun Cheung, Ying Xu, Matthew Cairns, Paul Milligan

Published in: BMC Medical Research Methodology | Issue 1/2017

Login to get access

Abstract

Background

In studies of recurrent events, it is common to consider a person who has suffered a disease episode and received curative treatment to be not at risk of suffering a new episode for a duration of time. It is a common practice to deduct this duration from the person’s observation time in the statistical analysis of the incidence data.

Methods

We examined the concepts of incidence and protective efficacy from a real life point of view. We developed simple formulae to show the relationship between the incidence rate and protective efficacy between analyses with and without deducting the curative treatment time from the observation time. We used a malaria chemoprevention and a malaria vaccine study, both previously published, to illustrate the differences.

Results

Applying the formulae we derived to a range of disease incidence that covered the two case studies, we demonstrated the divergence of the two sets of estimates when incidence rate is approximately 1 per person-year or higher. In the malaria chemoprevention study, incidence was 5.40 per person-year after the deduction of curative treatment time from observation time but 4.48 per person-year without the deduction. The chemoprevention offered 56.6 and 50.7% protection calculated with and without the deduction, respectively. In the malaria vaccine study, where disease incidence was much lower than one, the results between the two ways of analysis were similar. For answering real life questions about disease burden in the population in a calendar year and the reduction that may be achieved if an intervention is implemented, the definition without deduction of curative treatment time should be used.

Conclusions

The practice of deducting curative treatment time from observation time is not wrong, but it is not always the best approach. Investigators should consider the appropriateness of the two analytic procedures in relation to the specific research aims and the intended use of the results.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hennekens CH, Buring J. Epidemiology in medicine. Philadelphia: Lippincott Williams & Wilkins; 1987. Hennekens CH, Buring J. Epidemiology in medicine. Philadelphia: Lippincott Williams & Wilkins; 1987.
2.
go back to reference Smith P, Marrow RH. Field trials of health interventions in developing countries: a toolbox. London: Macmillan; 1996. Smith P, Marrow RH. Field trials of health interventions in developing countries: a toolbox. London: Macmillan; 1996.
3.
go back to reference Greenland S, Rothman KJ. Measures of occurrence. In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 32–50. Greenland S, Rothman KJ. Measures of occurrence. In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 32–50.
4.
go back to reference Porta M. A dictionary of epidemiology. Oxford: Oxford U.P; 2014. Online version.CrossRef Porta M. A dictionary of epidemiology. Oxford: Oxford U.P; 2014. Online version.CrossRef
5.
go back to reference Cameron AC, Trivedi PK. Regression analysis of count data. Cambridge: Cambridge U.P; 1998.CrossRef Cameron AC, Trivedi PK. Regression analysis of count data. Cambridge: Cambridge U.P; 1998.CrossRef
6.
go back to reference Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004;364:1411–20.CrossRefPubMed Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004;364:1411–20.CrossRefPubMed
7.
go back to reference Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet. 2005;366:2012–18.CrossRefPubMed Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet. 2005;366:2012–18.CrossRefPubMed
8.
go back to reference Bigira V, Kapisi J, Clark TD, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young ugandan children: a randomized controlled trial. PLoS Med. 2014;11:e1001689.CrossRefPubMedPubMedCentral Bigira V, Kapisi J, Clark TD, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young ugandan children: a randomized controlled trial. PLoS Med. 2014;11:e1001689.CrossRefPubMedPubMedCentral
9.
go back to reference Sagara I, Giorgi R, Doumbo OK, Piarroux R, Gaudrt J. Modelling recurrent events: comparison of statistical models with continuous and discontinuous risk intervals on recurrent malaria episodes data. Malar J. 2014;13:293.CrossRefPubMedPubMedCentral Sagara I, Giorgi R, Doumbo OK, Piarroux R, Gaudrt J. Modelling recurrent events: comparison of statistical models with continuous and discontinuous risk intervals on recurrent malaria episodes data. Malar J. 2014;13:293.CrossRefPubMedPubMedCentral
10.
go back to reference Cook RJ, Lawless JF. The statistical analysis of recurrent events. New York: Springer; 2007. Cook RJ, Lawless JF. The statistical analysis of recurrent events. New York: Springer; 2007.
11.
go back to reference Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.CrossRef Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.CrossRef
12.
go back to reference Enwere GC, Cheung YB, Zaman S, Akano A, Oluwalana C, Okoko B, Vaughan A, Adegbola R, Greenwood B, Cutts F. The epidemiology and clinical features of pneumonia according to radiographic findings in Gambian children. Trop Med Int Health. 2007;12:1377–85.CrossRefPubMed Enwere GC, Cheung YB, Zaman S, Akano A, Oluwalana C, Okoko B, Vaughan A, Adegbola R, Greenwood B, Cutts F. The epidemiology and clinical features of pneumonia according to radiographic findings in Gambian children. Trop Med Int Health. 2007;12:1377–85.CrossRefPubMed
13.
15.
go back to reference Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev. 1988;10:212–41.CrossRefPubMed Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev. 1988;10:212–41.CrossRefPubMed
16.
go back to reference Halloran ME, Longini IM, Struchiner CJ. Design and analysis of vaccine studies. New York: Springer; 2010.CrossRef Halloran ME, Longini IM, Struchiner CJ. Design and analysis of vaccine studies. New York: Springer; 2010.CrossRef
Metadata
Title
Evaluation of the impact of disease prevention measures: a methodological note on defining incidence rates
Authors
Yin-Bun Cheung
Ying Xu
Matthew Cairns
Paul Milligan
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2017
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-017-0350-4

Other articles of this Issue 1/2017

BMC Medical Research Methodology 1/2017 Go to the issue